For laboratory research use only. Not for human or veterinary use.
BioIntegrityPeptide Research

Vitality

PT-141 / Oxytocin

Peptide blend

PT-141 and Oxytocin blend

Research context

This preparation combines PT-141, a melanocortin receptor agonist, with oxytocin, a nonapeptide acting at the oxytocin receptor. The two act at unrelated receptor systems. Each component is characterised independently in the literature.

Common assays: Component identity by LC-MS · Purity per component

Specification

DesignationPeptide blend
Full namePT-141 and Oxytocin blend
ComponentsPT-141 (Bremelanotide) · Oxytocin
Formats10 mL Vial · 15 mL Advanced Liquid Peptide Spray
SolubilityVial: bacteriostatic water, sterile water. Spray: supplied in metered spray format.
StorageVial, lyophilised: −20 °C. Spray: refrigerated 2–8 °C, protected from light.
Current lotPT105N0526 →

PT-141 / Oxytocin COA: certificates of analysis by lot

2 lots of PT-141 / Oxytocin have a published certificate of analysis from AxisPharm, LLC, an independent laboratory. Each certificate reports the laboratory's results for that lot.

LotFormatPurity (HPLC-UV)Reported
PT105N052610 / 5 mg Spray99.1%2026-05-27
PO510N11255 mg / 10 mg Spray>99.0%2025-11-20

Common questions

How is a two-component blend verified?

Each component is identified and quantified separately by LC-MS and RP-HPLC, with results reported per component on the certificate.

Where can I see the PT-141 / Oxytocin certificate of analysis?

Every published PT-141 / Oxytocin lot has its own certificate page on this site, listed under "PT-141 / Oxytocin COA" above. There are 2 published lots; the most recent, lot PT105N0526, was reported on 2026-05-27 at 99.1% purity by HPLC-UV. The certificates are issued by AxisPharm, LLC, an independent laboratory.

Components, blends and pathway

Related compounds